Vaccines based on the cell surface carbohydrates of pathogenic bacteria (Q36128243)

12 August 2017

1 reference

title

Vaccines based on the cell surface carbohydrates of pathogenic bacteria (English)

1 reference

12 August 2017

Christopher Jones

1

1 reference

12 August 2017

9 May 2005

1 reference

Anais da Academia Brasileira de Ciências

12 August 2017

1 reference

12 August 2017

77

1 reference

12 August 2017

2

1 reference

12 August 2017

293-324

1 reference

Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report

12 August 2017

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : V. THE IMMUNOLOGICAL SPECIFITY OF AN ANTIGEN PREPARED BY COMBINING THE CAPSULAR POLYSACCHARIDE OF TYPE III PNEUMOCOCCUS WITH FOREIGN PROTEIN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Impact of meningococcal C conjugate vaccine in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Immunogenetic analysis of the immune response to pneumococcal polysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Candida albicans mannan-protein conjugate as vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Polysaccharide processing and presentation by the MHCII pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Safety and Immunogenicity of Escherichia coli 018 O-Specific Polysaccharide (O-PS)-Toxin A and O-PS-Cholera Toxin Conjugate Vaccines in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Pneumococcal conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

WHO and MSF appeal for funds for new meningitis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Human immunity to the meningococcus. I. The role of humoral antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Human immunity to the meningococcus. II. Development of natural immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Assessing efficacy of Haemophilus influenzae type b combination vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Variable region expression in the antibody responses of infants vaccinated with Haemophilus influenzae type b polysaccharide-protein conjugates. Description of a new lambda light chain-associated idiotype and the relation between idiotype expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Haemophilus influenzae type b conjugate vaccines: a review of efficacy data

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Enhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from Moraxella catarrhalis conjugated to proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Prophylactic and therapeutic efficacy of antibodies to a capsular polysaccharide shared among vancomycin-sensitive and -resistant enterococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Effectiveness of pneumococcal polysaccharide vaccine in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Analyzing the economic value of the hepatitis B?Haemophilus influenzae type B combination vaccine by reverse engineering a formulary selection algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Revised structures for the capsular polysaccharides from Staphylococcus aureus Types 5 and 8, components of novel glycoconjugate vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Structural studies of the capsular antigen from streptococcus pneumoniae type 26

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Antibody to the capsular polysaccharide/adhesin protects rabbits against catheter-related bacteremia due to coagulase-negative staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Salivary anti-capsular antibodies in infants and children immunised with Streptococcus pneumoniae capsular polysaccharides conjugated to diphtheria or tetanus toxoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Correlates of immunity for pneumococcal conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Full 1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from Neisseria meningitidis used in vaccine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Structural studies on the specific type-14 pneumococcal polysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Vaccine potential of poly-1-6 beta-D-N-succinylglucosamine, an immunoprotective surface polysaccharide of Staphylococcus aureus and Staphylococcus epidermidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Conjugation of meningococcal lipooligosaccharides through their lipid A terminus conserves their inner epitopes and results in conjugate vaccines having improved immunological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

T cell-independent antigens type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Structure of the type 5 capsular polysaccharide of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Conjugated heptavalent pneumococcal vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Determination of the molecular size distribution of Haemophilus influenzae type b-tetanus toxoid conjugate vaccines by size-exclusion chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Combination of DTP and Haemophilus influenzae type b conjugate vaccines can affect laboratory evaluation of potency and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Considerations for Formulating the Second-Generation Pneumococcal Capsular Polysaccharide Vaccine with Emphasis on the Cross-Reactive Types Within Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

21 January 2018

Meningococcal disease

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Location and quantitation of the sites of O-acetylation on the capsular polysaccharide from Streptococcus pneumoniae type 9V by 1H-n.m.r. spectroscopy: comparison with type 9A

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Prevention of Haemophilus influenzae type b infections in Apache and Navajo children

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Salmonella typhi O-polysaccharide--tetanus toxoid conjugated vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Pneumococcal disease: prospects for a new generation of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Structural analysis and chemical depolymerization of the capsular polysaccharide of Streptococcus pneumoniae type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Protection against endocarditis due to Staphylococcus epidermidis by immunization with capsular polysaccharide/adhesin

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Induction of Protective Immunity by SyntheticVibrio choleraeHexasaccharide Derived fromV. choleraeO1 Ogawa Lipopolysaccharide Bound to a Protein Carrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

Outer-membrane protein- and rough lipopolysaccharide-specific monoclonal antibodies protect mice against Brucella ovis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0001-37652005000200009

10.1590/S0001-37652005000200009

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15895165